Literature DB >> 16255659

Bupropion: risks and benefits.

Sarah Ross1, David Williams.   

Abstract

Cigarette smoking represents one of the most preventable causes of death worldwide. However, success rates for stopping smoking are disappointingly low and are associated with high relapse rates. There is a need for a successful form of smoking cessation therapy. Bupropion is an effective therapy for smoking cessation and is recommended as first-line treatment in both US and UK guidelines. Its mechanism of action in smoking cessation is unclear, although it is thought that dopaminergic pathways are involved in the 'reward' circuit of drug dependence. Seizures are an important adverse effect of bupropion and care is needed when used in other conditions or with other medication that can lower the seizure threshold. Bupropion has been shown to be a cost-effective therapy for smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16255659     DOI: 10.1517/14740338.4.6.995

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  7 in total

Review 1.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

2.  Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey.

Authors:  Sherry A McKee; Kelly C Young-Wolff; Emily L R Harrison; K Michael Cummings; Ron Borland; Christopher W Kahler; Geoffrey T Fong; Andrew Hyland
Journal:  Alcohol Clin Exp Res       Date:  2012-12-14       Impact factor: 3.455

3.  Seizures during antidepressant treatment in psychiatric inpatients--results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008.

Authors:  M Köster; R Grohmann; R R Engel; M A Nitsche; E Rüther; D Degner
Journal:  Psychopharmacology (Berl)       Date:  2013-09-26       Impact factor: 4.530

Review 4.  Nicotine vaccines to assist with smoking cessation: current status of research.

Authors:  Tobias Raupach; Philippe H J Hoogsteder; Constant P Onno van Schayck
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

5.  Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Frank T Leone; Yuqing Zhang; Sarah Evers-Casey; A Eden Evins; Michelle N Eakin; Joelle Fathi; Kathleen Fennig; Patricia Folan; Panagis Galiatsatos; Hyma Gogineni; Stephen Kantrow; Hasmeena Kathuria; Thomas Lamphere; Enid Neptune; Manuel C Pacheco; Smita Pakhale; David Prezant; David P L Sachs; Benjamin Toll; Dona Upson; Dan Xiao; Luciane Cruz-Lopes; Izabela Fulone; Rachael L Murray; Kelly K O'Brien; Sureka Pavalagantharajah; Stephanie Ross; Yuan Zhang; Meng Zhu; Harold J Farber
Journal:  Am J Respir Crit Care Med       Date:  2020-07-15       Impact factor: 21.405

Review 6.  The use of bupropion SR in cigarette smoking cessation.

Authors:  Scott Wilkes
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

7.  [Influence of propofol dose and blood components on duration of electrical seizures in electroconvulsive therapy].

Authors:  María Luisa González Moral; Carmen Selva Sevilla; Patricia Romero Rodenas; María Teresa Tolosa Pérez; Marta Lucas Pérez-Romero; Mar Domato Lluch; Manuel Gerónimo Pardo
Journal:  Braz J Anesthesiol       Date:  2018-08-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.